The role of sevelamer in achieving the kidney disease outcomes quality initiative (K/DOQI) guidelines for hyperphosphatemia
Authors:
- 27 April 2004
- journal article
- review article
- Published by Informa Healthcare in Current Medical Research and Opinion
- Vol. 20 (7) , 991-999
Abstract
SUMMARYBackground: End-stage renal disease (ESRD) is a chronic health care problem associated with multiple co-morbidities and escalating costs. Disregulation of mineral metabolism (principally hyperphosphatemia and hypercalcemia) contributes to substantial morbidity and mortality. Accordingly, new and more-aggressive Kidney Disease Outcomes Quality Initiative (K/DOQI) Guidelines from the National Kidney Foundation promote lower serum phosphorus (3.5–5.5 mg/dL), lower calcium (8.4–9.5 mg/dL), and lower calcium-phosphorus product (< 55 mg2/dL2) targets.Review findings: Traditional calcium-based and metal-based phosphate binders are effective but are associated with side effects and toxicity that limit their use. Achieving rigorous K/DOQI goals demands higher therapeutic doses of phosphate binders and may require more-aggressive use of calcium-free and metal-free phosphate binders. Sevelamer hydrochloride is a calcium- and metal-free polymer that binds phosphate effectively without contributing to calcium l...Keywords
This publication has 15 references indexed in Scilit:
- Hyperphosphataemia and treatment with sevelamer in haemodialysis patientsNephrology Dialysis Transplantation, 2003
- Calcium salts in the treatment of hyperphosphatemia in hemodialysis patientsCurrent Opinion in Nephrology and Hypertension, 2003
- Prevalence and socio-economic aspects of chronic kidney diseaseNephrology Dialysis Transplantation, 2002
- Management of disturbances of calcium and phosphate metabolism in chronic renal insufficiency, with emphasis on the control of hyperphosphataemiaNephrology Dialysis Transplantation, 2002
- The impact of improved phosphorus control: use of sevelamer hydrochloride in patients with chronic renal failureNephrology Dialysis Transplantation, 2002
- Clinical outcomes, quality of life, and costs in the North Thames Dialysis Study of elderly people on dialysis: a prospective cohort studyThe Lancet, 2000
- Coronary-Artery Calcification in Young Adults with End-Stage Renal Disease Who Are Undergoing DialysisNew England Journal of Medicine, 2000
- A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patientsAmerican Journal of Kidney Diseases, 1999
- Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: A national studyAmerican Journal of Kidney Diseases, 1998
- Calcium Acetate versus Calcium Carbonate as Phosphate Binders in Hemodialysis PatientsNephron, 1992